COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,796 Articles (22,527 medRxiv, 8,269 bioRxiv)

Most recent first Previous |  Page 884: Articles 8831-8840  | Next

Quantifying political influence on COVID-19 fatality in Brazil
de Almeida, L., Carelli, P., Cavalcanti, N. G., do Nascimento, J. D., Felinto, D.
10.1101/2022.02.09.22270714 — Posted: 2022-02-14
Unpacking COVID-19 and Conspiracy Theories in the UK Black Community
Vandrevala, T., Hendy, J., Hanson, K., Alidu, L., Ala, A.
10.1101/2022.02.12.22270438 — Posted: 2022-02-14
COVID-19 in Japan: insights from the first three months of the epidemic
Imai, N., Gaythorpe, K. A. M., Bhatia, S., Mangal, T. D., Cuomo-Dannenburg, G., Unwin, H. J. T., Jauneikaite, E., Ferguson, N. M.
10.1101/2022.02.10.22270735 — Posted: 2022-02-13
Empirical evidence of transmission over a school-household network for SARS-CoV-2; exploration of transmission pairs stratified by primary and secondary school.
van Iersel, S. C. J. L., Backer, J. A., van Gaalen, R. D., Andeweg, S. P., Munday, J. D., Wallinga, J., RIVM COVID-19 epidemiology and surveillance group, , van Hoek, A. J.
10.1101/2022.02.12.22270851 — Posted: 2022-02-13
Adequacy of serial self-performed SARS-CoV-2 rapid antigen-detection testing for longitudinal mass screening in the workplace
Papenburg, J., Campbell, J. R., Caya, C., Dion, C., Corsini, R., Cheng, M., Menzies, D., Yansouni, C. P.
10.1101/2022.02.10.22270805 — Posted: 2022-02-13
Multiple sclerosis disease-modifying therapies and COVID-19 vaccines: A practical review and meta-analysis
Etemadifar, M., Nouri, H., Pitzalis, M., Idda, M. L., Salari, M., Baratian, M., Mahdavi, S., Abhari, A. P., Sedaghat, N.
10.1101/2022.02.12.22270883 — Posted: 2022-02-13
Excess COVID-19 associated deaths among the unvaccinated population >= 18 years old in the US, May 30 through December 4, 2021
Jia, K. M., Hanage, B., Lipsitch, M., Swerdlow, D. L.
10.1101/2022.02.10.22270823 — Posted: 2022-02-13
Syndromic surveillance for severe acute respiratory infections (SARI) enables valid estimation of COVID-19 hospitalization incidence and reveals underreporting of hospitalizations during pandemic peaks of three COVID-19 waves in Germany, 2020-2021
Tolksdorf, K., Haas, W., Schuler, E., Wieler, L. H., Schilling, J., Hamouda, O., Diercke, M., Buda, S.
10.1101/2022.02.11.22269594 — Posted: 2022-02-13
Persistence of SARS-CoV-2 immunity, Omicron's footprints, and projections of epidemic resurgences in South African population cohorts.
Sun, K., Tempia, S., Kleynhans, J., Gottberg, A. v., McMorrow, M. L., Wolter, N., Bhiman, J. N., Moyes, J., Plessis, M. d., Carrim, M., Buys, A., Martinson, N. A., Kahn, K., Tollman, S., Lebina, L., Wafawanaka, F., Toit, J. d., Gomez-Olive, F. X., Mkhencele, T., Viboud, C., Cohen, C.
10.1101/2022.02.11.22270854 — Posted: 2022-02-13
Underdispersion in the reported Covid-19 case and death numbers may suggest data manipulations
Kobak, D.
10.1101/2022.02.11.22270841 — Posted: 2022-02-13

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).